Mario Sznol, MD, comments on the results of his phase 1 study reporting on data from patients with metastatic melanoma treated with nivolumab.
FDA approval of ramucirumab offers a new therapy option for patients with gastric cancer, which is notoriously aggressive and difficult disease to treat.
Editorial Board Member Don Dizon, MD, answers some questions about issues in breast cancer treatment today.
ChemotherapyAdvisor.com Editorial Board Member Don S. Dizon discusses survivorship issues from the 2013 Breast Cancer Symposium.
Editorial Advisory Board member Dr. Socinski discusses the key clinical insights brought to light by the POINTBREAK trial, presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
An expert reviews the new maintenance, second- and third-line therapies for colorectal cancer treatment presented at the 2013 Gastrointestinal Cancers Symposium.
In this article, Advisory Board member Neal Shore, MD, FACS, discusses barriers to clinicians recommending active surveillance for men with low-risk prostate cancer.
Several new therapies for metastatic colorectal cancer have been developed and refined, changing the way the disease can be treated.
Advisory Board Member Dr. Farma reviews the current recommendations for using sentinel lymph node biopsy in patients with melanoma.
This patient, who had an increasing PSA level, was found to have abnormal PCA3 urine test results.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|